EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Marked improvement in HbA1c following introduction of biosimilar insulin to treatment regimen of children and youth with type 1 diabetes in Mali: A randomised controlled trial

Stéphane Besançon, Aveni Haynes, Amagara Domon Togo, Jessica Lynn Sandy, Jayanthi Maniam, Asa Traoré Sidibe, Sylla Djéneba, Carine de Beaufort, Montserrat Castellsague Perolini, Giacomo Gastaldi, David Beran iD, Cecile Eigenmann und 1 weitere

Diabetic Medicine · 2025

DOI: 10.1111/dme.70007 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetic Medicine, 2025. Verfasst von Stéphane Besançon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Santé Diabète, Bamako, Mali. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glycated Hemoglobin, Biosimilar Pharmaceuticals, Hypoglycemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Leona M. and Harry B. Helmsley Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Evidence on outcomes of treating type 1 diabetes (T1D) with long‐acting basal insulins in low‐resourced settings is lacking. This study aimed to evaluate the impact of switching children and youth with T1D in the low‐income country of Mali from human insulin via syringe to long‐acting biosimilar insulin glargine delivered by reusable pens combined with short‐acting insulin via syringe.

Methods

A two‐group parallel design randomised trial was conducted enrolling 260 youth aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Glycated HemoglobinBiosimilar PharmaceuticalsHypoglycemic AgentsInsulin GlargineHumansAdolescentFemaleMaleMaliChildYoung AdultTreatment OutcomeChild, PreschoolInsulinDrug Substitution

Stichwörter der Autor:innen

adolescentschildreninsulin glarginetype 1 diabetes

Substanzen

Glycated HemoglobinBiosimilar PharmaceuticalsHypoglycemic AgentsInsulin Glarginehemoglobin A1c protein, humanInsulin

Autor:innen und Institutionen

  • Santé Diabète, Bamako, Mali.
  • Life for a Child Program, Diabetes Australia, Glebe, New South Wales, Australia.
  • Hôpital du Mali, Yirimadio, Bamako, Mali.
  • Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
  • Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Pediatric Clinic, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.

ORCID-Profile: David Beran

Förderung

  • Leona M. and Harry B. Helmsley Charitable Trust

Zitieren

APA

Besançon, S., Haynes, A., Togo, A. D., Sandy, J. L., Maniam, J., Sidibe, A. T., Djéneba, S., de Beaufort, C., Perolini, M. C., Gastaldi, G., Beran, D., Eigenmann, C., & Ogle, G. D. (2025). Marked improvement in HbA1c following introduction of biosimilar insulin to treatment regimen of children and youth with type 1 diabetes in Mali: A randomised controlled trial. Diabetic Medicine. https://doi.org/10.1111/dme.70007

Vancouver

Besançon S, Haynes A, Togo AD, Sandy JL, Maniam J, Sidibe AT, et al. Marked improvement in HbA1c following introduction of biosimilar insulin to treatment regimen of children and youth with type 1 diabetes in Mali: A randomised controlled trial. Diabetic Medicine. 2025. doi:10.1111/dme.70007

BibTeX
@article{Besanon2025,
  author = {Besançon, Stéphane and Haynes, Aveni and Togo, Amagara Domon and Sandy, Jessica Lynn and Maniam, Jayanthi and Sidibe, Asa Traoré and Djéneba, Sylla and de Beaufort, Carine and Perolini, Montserrat Castellsague and Gastaldi, Giacomo and Beran, David and Eigenmann, Cecile and Ogle, Graham David},
  title = {Marked improvement in HbA1c following introduction of biosimilar insulin to treatment regimen of children and youth with type 1 diabetes in Mali: A randomised controlled trial},
  journal = {Diabetic Medicine},
  year = {2025},
  doi = {10.1111/dme.70007}
}
Kostenlos starten →